NewsBenzinga革命药物公司开始在 RASolute 309 全球随机 III 期临床试验中治疗患者，评估 RASONQUE 与 Zoldonrasib 联合作为转移性 RAS G12D 胰腺导管腺癌成人患者的一线治疗方案 革命药物公司开始在 RASolute 309 全球随机 III 期临床试验中治疗患者，评估 RASONQUE 与 Zoldonrasib 联合作为转移性 RAS G12D 胰腺导管腺癌成人患者的一线治疗方案 Benzinga 2026.10.05 12:02 (GMT+0) Open on Benzinga Other news Jones Trading Maintains Buy on Dynex Cap, Lowers Price Target to $12.5 Here's How Much $100 Invested In Gartner 20 Years Ago Would Be Worth Today Microsoft says AI agents are like insider threats as ‘frontier models can’t be trusted’ Dorchester Minerals Enters Into An Agreement To Acquire Mineral And Royalty Interests; To Buy ~ 4,300 Net Royalty Acres In Williston Basin, North Dakota; Interests To Be Exchanged For 1,250,000 Common Units Of Dorchester Minerals Here's How Much $100 Invested In Fastenal 10 Years Ago Would Be Worth Today Bernstein Just Upgraded Datadog Stock. Here's Why.
Dorchester Minerals Enters Into An Agreement To Acquire Mineral And Royalty Interests; To Buy ~ 4,300 Net Royalty Acres In Williston Basin, North Dakota; Interests To Be Exchanged For 1,250,000 Common Units Of Dorchester Minerals
